A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fasting conditions
A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fasting conditions: open label, single-dose, randomized, two-period, two-treatment, two-sequence, crossover, comparative bioavailability study
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
77
Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Pharma medica research Inc.
Mississauga, Ontario, Canada
Maximum Plasma Concentration (Cmax)
Time frame: 0-72 hours
Area under the plasma concentration versus time curve (AUC)
Time frame: 0-72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.